LY2181308 + idarubicin + cytarabine

**LY2181308 + idarubicin + cytarabine** is an investigational combination regimen used in clinical trials for acute myeloid leukemia (AML), particularly in refractory or relapsed cases. The combination includes: - **LY2181308**: a sodium antisense oligonucleotide that targets and inhibits survivin expression, a protein involved in mitosis and inhibition of apoptosis in tumor cells. Suppression of survivin may restore apoptotic pathways and contribute to cell cycle arrest in AML[1][3]. - **Idarubicin**: a synthetic anthracycline antibiotic, acts as a DNA intercalator and topoisomerase II inhibitor, impairing DNA synthesis and promoting apoptosis in rapidly dividing cells[2][5]. - **Cytarabine**: a nucleoside analog, incorporates into DNA during replication and inhibits DNA polymerase, resulting in DNA damage and cell death, particularly effective in leukemic blasts[2][5]. LY2181308 alone is generally well tolerated, and when combined with idarubicin and cytarabine, it does not appear to increase toxicity beyond what is usually observed with chemotherapy. Clinical trials in relapsed/refractory AML reported complete and partial remissions, cytoreduction, and a safety profile consistent with historical idarubicin/cytarabine regimens, with the antisense agent aiming to enhance apoptosis by targeting survivin[1][3].